ClinicalTrials.gg

Program

luprolide acetate gel depot

Also written as “Leuprolide Open Label”, “Eligard® 45 mg” and “Eligard”.

Its studies are mostly in Prostatic Neoplasms, led by 3 companies.

Furthest: phase 4, since Jan 13, 20124 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical21 open or runningphase 4since Jan 13, 2012Jan 13, 2012none ahead
Astellas Pharma10 open or runningphase 4since Aug 28, 2013Aug 28, 2013none ahead
Pfizer11 open or runningphase 3since Dec 14, 2014Dec 14, 2014none ahead

Also a collaborator on its studies: Medivation LLC, a wholly owned subsidiary of Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2012First study: phase 4 study in Prostatic NeoplasmsNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT01511874 · 42 enrolled · Korea, Republic of
  2. Aug 28, 2013Astellas Pharma’s first study: phase 4 study in Prostatic NeoplasmsNew to Astellas PharmaAstellas Pharma · NCT01933022 · 1 enrolled · Netherlands
  3. Dec 14, 2014Pfizer’s first study: phase 3 study in Prostatic NeoplasmsNew to PfizerPfizer · NCT02319837 · 1,068 enrolled · United States, Australia, Austria and more
  4. Apr 8, 2025Phase 4 study in CPPDaewoong Pharmaceutical · NCT06926933 · 50 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06926933CPP · South Korea4Active, not recruitingDaewoong PharmaceuticalJun 15, 202650
NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingPfizerJan 31, 20231,068
NCT01933022Prostatic Neoplasms · Netherlands4TerminatedAstellas PharmaAug 20151
NCT01511874Prostatic Neoplasms · Korea, Republic of4CompletedDaewoong PharmaceuticalMay 201342

How it is read

Names in the registry

  • “Leuprolide Open Label”, 1 entry
  • “Eligard® 45 mg”, 1 entry
  • “Eligard”, 1 entry
  • “ELIGARD 22.5mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.